Pages that link to "Q33864571"
Jump to navigation
Jump to search
The following pages link to Treatment of relapsed and refractory acute myelogenous leukemia (Q33864571):
Displaying 50 items.
- A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome (Q27024786) (← links)
- Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy (Q30399209) (← links)
- Combination chemotherapy utilizing continuous infusion of intermediate-dose cytarabine for refractory or recurrent acute myeloid leukemia (Q32065363) (← links)
- Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy (Q33392185) (← links)
- A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome (Q33769335) (← links)
- Relapsed acute myeloid leukemia: why is there no standard of care? (Q33877202) (← links)
- Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia (Q34185528) (← links)
- Allogeneic hematopoietic cell transplantation for acute leukemia in first relapse or second remission (Q34316852) (← links)
- Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia (Q34358512) (← links)
- Therapeutic options for acute myelogenous leukemia (Q34380840) (← links)
- Acute leukemia (Q34588059) (← links)
- Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience (Q34772229) (← links)
- Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia (Q34774158) (← links)
- Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia (Q34983843) (← links)
- Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients (Q35077929) (← links)
- Reduced drug incorporation into DNA and antiapoptosis as the crucial mechanisms of resistance in a novel nelarabine-resistant cell line (Q35214520) (← links)
- The therapy of relapsed acute leukaemia in adults (Q35610850) (← links)
- Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias (Q36075766) (← links)
- Biology and management of relapsed acute myeloid leukaemia. (Q36085026) (← links)
- Cloretazine for the treatment of acute myeloid leukemia (Q36407434) (← links)
- MicroRNA-mRNA Pairs Associated with Outcome in AML: From In Vitro Cell-Based Studies to AML Patients (Q36511384) (← links)
- Bryostatin-1, Fenretinide and 1α,25 (OH)(2)D(3) Induce Growth Inhibition, Apoptosis and Differentiation in T and B Cell-Derived Acute Lymphoblastic Leukemia Cell Lines (CCRF-CEM and Nalm-6) (Q36571416) (← links)
- Salvage therapy for relapsed or refractory acute myeloid leukemia (Q36612564) (← links)
- Acute myeloid leukaemia (Q36663603) (← links)
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome. (Q36682845) (← links)
- The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients (Q36832124) (← links)
- Temozolomide and cisplatin in relapsed/refractory acute leukemia (Q37223615) (← links)
- Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia (Q37383528) (← links)
- Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia (Q37462852) (← links)
- Laromustine (cloretazine). (Q37693943) (← links)
- Allogeneic stem cell transplant in adult patients with acute myelogenous leukemia: a systematic analysis of international guidelines and recommendations (Q37842488) (← links)
- Effects of PPARγ Ligands on Leukemia (Q38017661) (← links)
- Late-phase investigational approaches for the treatment of relapsed/refractory acute myeloid leukemia (Q38042705) (← links)
- Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment? (Q38909191) (← links)
- Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice (Q38968878) (← links)
- Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission (Q39002077) (← links)
- Fractionated gemtuzumab ozogamicin combined with intermediate-dose cytarabine and daunorubicin as salvage therapy in very high-risk AML patients: a bridge to reduced intensity conditioning transplant? (Q39067366) (← links)
- A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia (Q39240258) (← links)
- Outcome of patients with acute myelogenous leukemia after second salvage therapy (Q40411708) (← links)
- Efficacy and safety of gemtuzumab ozogamicin in patients with poor-prognosis acute myeloid leukemia (Q40569180) (← links)
- A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML). (Q40614153) (← links)
- N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL). (Q40676167) (← links)
- Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy. (Q40725017) (← links)
- FLAMSA reduced-intensity conditioning is equally effective in AML patients with primary induction failure as well as in first or second complete remission (Q40777838) (← links)
- A prognostic model for survival after salvage treatment with FLAG-Ida +/- gemtuzumab-ozogamicine in adult patients with refractory/relapsed acute myeloid leukaemia. (Q40780156) (← links)
- Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia (Q41044948) (← links)
- New treatments and strategies in acute myeloid leukemia (Q41881090) (← links)
- Clofarabine combinations as acute myeloid leukemia salvage therapy (Q42048738) (← links)
- Upregulation of miR-142-3p Improves Drug Sensitivity of Acute Myelogenous Leukemia through Reducing P-Glycoprotein and Repressing Autophagy by Targeting HMGB1 (Q42090608) (← links)
- The prognostic impact of FLT3-ITD and NPM1 mutations in patients with relapsed acute myeloid leukemia and intermediate-risk cytogenetics. (Q42142418) (← links)